950577-02-3 Usage
General Description
6-Bromo-7-fluoroquinazolin-4-ol is a chemical compound with the molecular formula C9H5BrF2N2O. It is a quinazoline derivative, and its structure includes a quinazoline ring with bromine and fluorine substituents. 6-BROMO-7-FLUOROQUINAZOLIN-4-OL may have potential pharmaceutical applications due to its structural and chemical properties, including its ability to interact with biological systems and its potential as a building block for the synthesis of more complex molecules. Additionally, its bromine and fluorine substituents may contribute to its pharmacological properties and reactivity in chemical reactions. Further research and testing would be needed to fully understand its potential uses and effects.
Check Digit Verification of cas no
The CAS Registry Mumber 950577-02-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,0,5,7 and 7 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 950577-02:
(8*9)+(7*5)+(6*0)+(5*5)+(4*7)+(3*7)+(2*0)+(1*2)=183
183 % 10 = 3
So 950577-02-3 is a valid CAS Registry Number.
950577-02-3Relevant articles and documents
An alternative synthesis of the non-small cell lung carcinoma drug afatinib
Kovacevic, Tatjana,Mesic, Milan,Avdagic, Amir,Zegarac, Miroslav
supporting information, p. 4180 - 4182 (2018/10/24)
Afatinib (BIBW2992) is the anticancer drug developed by Boehringer Ingelheim. This work is reporting the synthesis of the afatinib using a new route by Ullmann-Goldberg reaction from corresponding 4-anilinoquinazoline iodide as the last step in the synthesis. This route was not described previously and it could be used for synthesis of afatinib analogues.
HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS
-
Page/Page column 81, (2011/11/06)
The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.
